Valuation: MannKind Corporation

Capitalization 1.14B 981M 914M 850M 1.57B 98.42B 1.75B 11.04B 4.17B 46.14B 4.29B 4.2B 170B P/E ratio 2025 *
19.4x
P/E ratio 2026 * 14.7x
Enterprise value 1.14B 981M 914M 850M 1.57B 98.42B 1.75B 11.04B 4.17B 46.14B 4.29B 4.2B 170B EV / Sales 2025 *
3.59x
EV / Sales 2026 * 3.13x
Free-Float
98.17%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-3.59%
1 week-0.27%
Current month+0.53%
1 month-1.31%
3 months-17.18%
6 months-37.44%
Current year-41.52%
More quotes
1 week 3.75
Extreme 3.75
4.05
1 month 3.51
Extreme 3.51
4.05
Current year 3.51
Extreme 3.51
6.68
1 year 3.51
Extreme 3.51
7.63
3 years 2.91
Extreme 2.91
7.63
5 years 1.52
Extreme 1.52
7.63
10 years 0.67
Extreme 0.6662
28
More quotes
Manager TitleAgeSince
Chief Executive Officer 48 24/05/2017
Director of Finance/CFO 50 21/04/2024
Chief Tech/Sci/R&D Officer 58 30/09/2022
Director TitleAgeSince
Director/Board Member 81 30/09/2003
Director/Board Member 81 30/11/2003
Chairman 69 08/12/2020
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-3.59%-0.27%-34.27%-1.57% 1.14B
+0.24%+2.39%+15.57%+35.09% 35.09B
+1.95%+7.06%+110.02%-19.87% 32.89B
-0.92%-2.54%+27.38%-31.68% 27.09B
-1.55%+4.46%+36.63%+353.38% 19.48B
-5.18%+4.80%+168.72%+2,260.36% 19.46B
+0.86%+24.29%+249.57%+515.75% 16.09B
+0.88%+7.13%+154.00%-62.61% 14.8B
-0.07%+3.01%-23.33%-44.07% 13.63B
-0.89%-0.87%+97.12%+106.17% 12.13B
Average -0.83%+4.83%+80.14%+311.10% 19.18B
Weighted average by Cap. -0.38%+4.75%+83.52%+305.74%
See all sector performances

Financials

2025 *2026 *
Net sales 318M 273M 254M 237M 437M 27.41B 488M 3.07B 1.16B 12.85B 1.19B 1.17B 47.24B 365M 314M 292M 272M 501M 31.47B 560M 3.53B 1.33B 14.76B 1.37B 1.34B 54.24B
Net income 61.82M 53.04M 49.42M 45.98M 84.84M 5.32B 94.73M 597M 225M 2.5B 232M 227M 9.18B 83.37M 71.53M 66.64M 62.01M 114M 7.18B 128M 805M 304M 3.37B 313M 306M 12.37B
Net Debt - -
More financial data * Estimated data
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
405
More about the company
Date Price Change Volume
18/07/25 3.760 $ -3.59% 2,315,224
17/07/25 3.900 $ -1.52% 1,888,800
16/07/25 3.960 $ +2.86% 2,895,415
15/07/25 3.850 $ -4.47% 2,916,398
14/07/25 4.030 $ +6.90% 2,973,096

Delayed Quote Nasdaq, July 18, 2025 at 09:00 pm

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.760USD
Average target price
9.375USD
Spread / Average Target
+149.34%
Consensus

Quarterly revenue - Rate of surprise